Trial: 202004125

A First-in-Human, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of IMC-002 in Subjects with Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas

Phase

I

Principal Investigator

Park, Haeseong

Disease Site

Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin Lymphoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Lung Cancer – Non-small Cell; Lung Cancer – Small Cell; Melanoma, Skin; Non-Hodgkin Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Sarcoma; Small Intestine; Soft Tissue; Stomach; Thyroid; Urinary Bladder

Learn more about this study at: clinicaltrials.gov